|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Vir Biotechnology, Inc. (VIR) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,390,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$246,341 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
85,714 |
171,399 |
296,953 |
6,004,552 |
| Total Sell Value |
$820,809 |
$1,715,710 |
$4,867,158 |
$153,876,604 |
| Total People Sold |
4 |
6 |
8 |
11 |
| Total Sell Transactions |
4 |
11 |
16 |
122 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sharp Philip A |
Director |
– • – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
88,888 |
105,368 |
|
- |
|
| Arch Venture Partners Ix, L.p. |
10% Owner |
– – • |
2019-10-16 |
4 |
B |
$20.00 |
$20,000,000 |
I/I |
1,000,000 |
1,000,000 |
1.5 |
- |
|
| Arch Venture Partners Ix, L.p. |
10% Owner |
– – • |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
27,222,219 |
15,555,554 |
|
- |
|
| More Robert J |
Director |
– • – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
60,822 |
60,822 |
|
- |
|
| More Robert J |
Director |
– • – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,944,443 |
1,944,443 |
|
- |
|
| Platinum Falcon B 2018 Rsc Ltd |
Former 10% Owner |
– – – |
2019-10-16 |
4 |
B |
$20.00 |
$20,000,000 |
D/D |
1,000,000 |
3,666,666 |
2.44 |
- |
|
| Platinum Falcon B 2018 Rsc Ltd |
Former 10% Owner |
– – – |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,666,666 |
2,666,666 |
|
- |
|
| Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
– – • |
2019-10-16 |
4 |
B |
$20.00 |
$19,000,000 |
I/I |
950,000 |
22,616,666 |
1.5 |
- |
|
| Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
– – • |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
21,666,666 |
21,666,666 |
|
- |
|
| Bill & Melinda Gates Foundation |
|
• • • |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,777,777 |
2,777,777 |
|
- |
|
| Alaska Permanent Fund Corp |
|
• • • |
2019-10-16 |
4 |
B |
$20.00 |
$30,000,000 |
D/D |
1,500,000 |
5,555,556 |
0.01 |
- |
|
| Alaska Permanent Fund Corp |
|
• • • |
2019-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
4,055,556 |
5,555,556 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,669,110 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,480 |
|
- |
|
| Kamarck Michael E. |
Chief Technology OfficerOffice |
• – – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
166,666 |
|
- |
|
| Scangos George A |
President and CEOOfficer |
• • – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,222,222 |
|
- |
|
| Scangos George A |
President and CEOOfficer |
• • – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,398,666 |
|
- |
|
| Frueh Klaus |
Director |
– • – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
144,444 |
|
- |
|
| Frueh Klaus |
Director |
– • – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
77,777 |
|
- |
|
| Pang Phillip |
Chief Medical OfficerOfficer |
• – – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,777 |
|
- |
|
| Parrish Jay |
Chief Business OfficerOfficer |
• – – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
222,222 |
|
- |
|
| Burow Kristina |
Director |
– • – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
444,444 |
|
- |
|
| Arch Venture Fund Ix, L.p. |
10% Owner |
– – • |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
444,444 |
|
- |
|
| Horn Howard |
CFOOfficer |
• – – |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
277,777 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2019-10-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
444,444 |
|
- |
|
575 Records found
|
|
Page 23 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
